When it comes to leading dividend growth stocks, many comes to mind, especially the widely held consumer staple stocks. However, due to their popularity, many have arguably moved ahead in terms of valuation and potential upside.
On the contrary, AbbVie (ABBV 1.94%)While one of the famous dividend stocks S&P 500Still not overrated. It continues to offer investors a great mix of value, growth and yield.
Image Source: Getty Images.
AbbVie at a glance
Based in North Chicago, Illinois, AbbVie went public in 2013, when Abbott Laboratories Shut down his pharmaceutical business. Because of its connection to Abbott, AbbVie “inherited” Abbott’s dividend history. Five years ago, Abbott reached Dividend King status when its annual dividend increase marked the 50th consecutive year. Because of this, AbbVie is also considered the Dividend King.
today’s change
(-1.94%) $-4.41
current price
$222.82
key data points
market cap
$401B
day limit
$222.73 -$228.58
52wk range
$181.73 -$244.81
volume
63.4K
average volume
6.6M
gross margin
70.58%
dividend yield
2.97%
AbbVie’s dividend growth history shows that it is maintaining its tradition as a reliable dividend stock. Since the spinoff 13 years ago, AbbVie has increased its quarterly cash payout from $0.40 per share to $1.73 per share. This equates to approximately 12% annual dividend growth since going public.
With its strong dividend-growth track record, the stock offers a relatively high yield considering its share price. Currently, AbbVie’s forward dividend yield is around 3%. In terms of valuation, the stock trades at around 16 times forward earnings.
Compared to shares of other top pharma stocks, it may seem expensive. For example, competitors prefer bristol myers squibb And Pfizer Trade for approximately 9x forward earnings. However, these lower-priced competitors face greater uncertainty regarding near-term results. AbbVie, on the other hand, has faced this uncertainty before, but not anymore, and is expected to continue to grow earnings in the coming years.
What Makes It a Dividend Standout Among Health Care Stocks
a major reason for so many pharmaceutical stock Trading at high-single-digit or low-teens forward multiples is contingent on upcoming patent expirations for many blockbuster branded drugs. Big names in the sector are struggling to refill their pipelines, whether organically or through strategic acquisitions.
Previously, AbbVie was facing this issue, commonly known as patent cliff. Although it initially delayed ending market exclusivity for its blockbuster drug Humira, by 2023 biosimilars began flooding the market, driving down sales. However, thanks to the success of two drugs from the company’s immunology portfolio, Skyrizi and Rinvoq, AbbVie has continued to offset Humira’s sales decline.
After reporting adjusted earnings of about $10 per share in 2025, adjusted earnings are expected to reach $14.24 per share this year and $16.23 per share in 2027. Compare that to Pfizer, which analysts say will see earnings decline 8% and 4% in 2026 and 2027, respectively. .
As rising earnings bring AbbVie’s payout ratio to 42%, which is within sustainable levels, investors are likely to continue seeing increases in the dividend, which has averaged 5% to 6% in recent years. The increasing payout, combined with steady earnings growth, points to a strong potential for solid returns over a multi-year time frame. With These Attractive Fundamentals, Consider AbbVie Leading Dividend Growth health care stocks.
